Look Below the Surface

With Molecular Testing

Back to Key Publications

Molecular analysis of pancreatic cyst fluid changes clinical management

Arner DM, Corning BE, Ahmed AM, Ho HC, Weinbaum BJ, et al.
Endosc Ultrasound. 2018;7:29-33.

This retrospective study evaluated the impact of PancraGEN on management decisions for patients with pancreatic cysts. Cases were presented to two pancreaticobiliary surgeons first without and then later with PancraGEN results, after a re-blinding period between the two instances. The two surgeons were asked to record their management recommendations in both instances. After viewing PancraGEN results, the two surgeons changed their recommended management of patients in 28% and 26% of cases, respectively. Management recommendations were changed more frequently (40% of cases) in patients who had intermediate cyst fluid CEA (45-800 ng/mL) levels and for those without an available CEA result, which can occur when cyst fluid volume is too low for CEA testing.

View Paper

Request Information

If you are a physician and would like to learn more about PancraGEN®, PanDNA®, or Interpace Diagnostics services, you can reach us using the form below.
I am interested in:
(Needed for verification purposes to allow representative follow‑up)
Request Info

Limitations and Disclaimers1
Although PancraGEN is highly specific for malignancy, some malignant cysts may not be detected. There may also be individuals who are falsely identified as having a malignant cyst. Diagnosis and appropriate patient management are the responsibility of the referring physician or healthcare provider.

Reference 1. Al-Haddad MA, Kowalski T, Siddiqui A, et al. Integrated molecular pathology accurately determines the malignant potential of pancreatic cysts. Endoscopy. 2015;47(2):136-142. 

Interpace Diagnostics is a registered trademark and business unit of Interpace Biosciences, Inc.™
©2022 Interpace Biosciences, Inc.™ All rights reserved.
Privacy Policy | HIPAA Privacy

Scroll to Top